Risk screening for HPV after LEEP
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at how to sort people into higher- or lower-risk groups after abnormal HPV testing treatment (LEEP), using repeat HPV and Pap (cytology) tests. It may help improve follow-up plans by identifying who needs closer monitoring after LEEP.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a positive HPV screening result and be in the 50–64 age range.
- You need follow-up testing 6 months after a LEEP procedure done in Denmark (Central Denmark Region), using HPV and Pap (cytology).
- You need another follow-up test 12 months after LEEP, using HPV and Pap (cytology).
- Your study records must include a valid “cytology triage” result.
- You must not be listed as someone who rejected research participation in the study registry.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a detailed DNA test to look for high-risk HPV in people with long-lasting (chronic) infection after treatment or with return of abnormal cells. It may help improve how clinicians monitor high-risk HPV and decide next steps.
This Phase 3 study tests whether getting the HPV vaccine after a LEEP procedure helps prevent the cervical problem from coming back. You may be eligible if you had a high-grade cervical pre-cancer or very early cancer, and have not had an HPV vaccine before.
This study looks at how a common cervical procedure called LEEP affects your sexual health and quality of life. It follows women who need a LEEP for the first time to see how they feel afterward.
This trial collects blood samples from women with HPV-related cervical cancer to see if a test can detect tiny bits of cancer DNA (molecular residual disease) and predict if the cancer might come back. Finding this DNA early could help guide future treatment decisions.
This early (Phase 1) study tests a new treatment for people with long-lasting mild abnormal Pap test results (ASC-US or LSIL) who also have HPV16 found on testing. It aims to find out whether the treatment can be given safely and may affect the HPV and abnormal cell changes.
This study looks at whether monitoring HPV DNA in your blood after surgery can help predict if cervical cancer comes back, and whether this information can guide decisions about extra treatment. If you join, you'll provide blood samples before and after surgery to track your HPV levels.
Hear when a new Cervix Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.